Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.1652W HIGH $15.06
Volume
55.65 M
Value Traded
825.79 M
Short % Float
9.9%
Days to Cover
1.9
+0.27%Week
+0.95%1 Month
+57.87%3 Month
+78.8%6 Month
-38.24%5 Year
-25.8%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.20 B
EPS (TTM)
-3.61
P/E Ratio
-
Ent. Value
1.68 B
Total Shares
148.49 M
Float Shares
146.01 M
Insiders
3.20%
Institutions
106.17%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
ETNB Catalyst Timeline
Dated clinical, regulatory and corporate events for 89bio, Inc.
Past FDA Catalysts and PDUFA Decisions
How ETNB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | Pegozafermin (FGF21 analog) | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pegozafermin Monoclonal antibodyNCT06419374 | Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis | Phase 3 | RECRUITING | 1,800 | Aug 31, 2031 | ||||||
| Pegozafermin Monoclonal antibodyNCT06318169 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis | Phase 3 | RECRUITING | 1,350 | Feb 1, 2029 | ||||||
| Pegozafermin Small moleculeCompletedNCT04541186 | Severe Hypertriglyceridemia | Phase 3 | COMPLETED | 455 | May 31, 2022 | ||||||
| BIO89-100 Small moleculeCompletedNCT05022693 | NASH - Nonalcoholic Steatohepatitis | Phase 2 | COMPLETED | 230 | Dec 21, 2021 | ||||||
| Pegozafermin Small moleculeCompletedNCT04048135 | NASH | Phase 1/2 | COMPLETED | 101 | Jan 19, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every ETNB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| pegozafermin Breakthrough | Nonalcoholic Steatohepatitis (NASH) | Phase 2b | 2024-02-29 | sustained benefits of pegozafermin at week 48 in patients with advanced NASH, which was consistent across patient sub-groupsRead More | bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates Plan to initiate the Phase 3 ENLIGHTEN NASH program for non-cirrhotic (F2-F3) and cirrhotic (F4) patients in the first and seRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Martins RyanOfficer (Chief Financial Officer) | Option | 76,901 335,397 held | $3.11 | 10/22/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in ETNB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 3.6 % (9.1 %) | 292.38 M | 19.89 M |
Ownership Trends
ETNB Short Interest
Shares sold short, counted twice a month.
9.9%
Short % of Float
of tradable shares sold short
6.8M
Shares Sold Short
-22.4% vs prior count
1.9 Low
Days to Cover
trading days of normal volume to buy every short share back
3.5M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ETNB ranks across every disease it competes in
Competitive Position is a premium feature
See how ETNB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialETNB News
About 89bio, Inc.
Founded11-11-2019
BIOPHARMAWATCH ELITE PLUS
Trade the next ETNB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime